| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Selling, general and administrative | 1,933 | 3,258 | ||
| Research and development | 597 | 1,064 | ||
| Change in fair value of contingent consideration | -37 | 16 | ||
| Total operating costs and expenses | 2,493 | 4,338 | ||
| (loss) income from operations | -2,493 | -4,338 | ||
| Change in fair value of convertible notes | -1,877 | -1,854 | ||
| Change in fair value of warrants | 236 | 542 | ||
| Other income, net | 68 | 92 | ||
| Total other (loss) income, net | -2,045 | -2,304 | ||
| (loss) income before taxes | -4,538 | -6,642 | ||
| Net (loss) income | -4,538 | -6,642 | ||
| Earnings per share, basic | -0.39 | -0.6 | ||
| Earnings per share, diluted | -0.39 | -0.6 | ||
| Weighted average number of shares outstanding, basic | 11,634,946 | 11,090,809 | ||
| Weighted average number of shares outstanding, diluted | 11,634,946 | 11,090,809 | ||
AEON Biopharma, Inc. (AEON)
AEON Biopharma, Inc. (AEON)